Skip to search formSkip to main contentSkip to account menu

Tiludronate

Known as: (chloro-4-phenyl)thiomethylene biphosphonate, (chloro-4-phenyl)thiomethylene bisphosphonate 
National Institutes of Health

Related topics

Related topics

5 relations
DiphosphonatesDrug AllergyPaget Disease Extramammary

Narrower (1)

Tiludronate disodium

Broader (1)

tiludronic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Review
2004
Review
2004
From Molds and Macrophages to Mevalonate: A Decade of Progress in Understanding the Molecular Mode of Action of Bisphosphonates
  • M. Rogers
  • Calcified Tissue International
  • 2004
  • Corpus ID: 24438016
Although bisphosphonates were first used as therapeutic agents to inhibit bone resorption in the early 1970s, their mode of… 
Review
2003
Review
2003
New insights into the molecular mechanisms of action of bisphosphonates.
  • M. Rogers
  • Current pharmaceutical design
  • 2003
  • Corpus ID: 22525479
Bisphosphonates are currently the most important and effective class of anti-resorptive drugs available, but the exact molecular… 
Highly Cited
2000
Highly Cited
2000
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI‐298
Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their… 
Review
2000
Review
2000
Oral bisphosphonates
This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer… 
Highly Cited
2000
Highly Cited
2000
Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment.
Review
1999
Review
1999
Bisphosphonates: from the laboratory to the clinic and back again.
Highly Cited
1996
Highly Cited
1996
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+‐ATPase
Although bisphosphonates have been shown to be potent inhibitors of osteoclast‐mediated bone resorption in vivo and in vitro and… 
Highly Cited
1995
Highly Cited
1995
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
OBJECTIVE To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of… 
Highly Cited
1995
Highly Cited
1995
Therapeutic strategy in Paget's disease of bone.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)